Rani Therapeutics Holdings Inc. (RANI)
RANI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/0001193125-26-126417-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RANI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001856725 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | CALIFORNIA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.6M |
| Net income | -$29.7M |
| Operating income | -$38.3M |
| Net margin | -1817.1% |
| Operating margin | -2346.0% |
| Revenue growth | +58.9% |
| Cash | $18.6M |
| Total assets | $58.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 46.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $3.6M cash; operating cash flow -$5.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 139,460,921 (2026-10-31); 121,511,580 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-05-27 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-11-12 |
| Auditor | CBIZ CPAs P.C., San Francisco, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.3M, sold $15.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.7M | -$7.7M | -$7.8M | $3.6M | No debt tags | $6.6M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $1.7M | -$7.4M | -$9.0M | $4.9M | No debt tags | $4.9M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $1.7M | -$7.0M | -$6.5M | $9.6M | No debt tags | $3.2M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $1.5M | -$10.3M | $294K | $18.6M | $0 | $1.6M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $0 | -$5.4M | -$5.1M | $4.1M | $13.8M | $1.2M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $0 | -$6.7M | -$5.8M | $10.2M | $17.5M | $1.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $172K | -$7.3M | -$8.1M | $10.1M | $21.3M | $1.2M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $1.0M | -$8.9M | -$8.7M | $3.8M | $25.0M | $1.0M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-27 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy DEFA 14A | DEFA14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 384 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.8% |
| 1 month | -28.2% |
| 3 months | -34.1% |
| Year to date | -61.0% |
| 1 year | -72.7% |
| From 52-week high | -72.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KALA | KALA BIO Inc. | $3.83 | -8.02% | $74.1M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| CPIX | Cumberland Pharmaceuticals Inc. | $5.21 | -11.39% | $78.1M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| PLYX | Polaryx Therapeutics Inc. | $1.67 | -6.99% | $83.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier